alprazolam has been researched along with Panic Disorder in 190 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to ascertain the relationship of alprazolam plasma levels and an anxiety-prone cognitive style to the characteristics and severity of early withdrawal after abrupt discontinuation of alprazolam in 26 patients with panic disorder." | 9.12 | Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. ( Antal, EJ; Barnhill, J; Javaid, JI; Matuzas, W; Qualls, C; Starcevic, V; Uhlenhuth, EH, 2006) |
| "Anxiolytic therapy with the benzodiazepine alprazolam is an established therapy in patients with panic disorder." | 9.12 | Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders. ( Béchir, M; Binggeli, C; Büchi, S; Buddeberg, C; Caduff, C; Chenevard, R; Lüscher, TF; Noll, G; Schwegler, K, 2007) |
| "This study compares the speed of onset of action of the extended release (XR) formulation of alprazolam with that of the compressed tablet (CT) formulation in a sample of outpatients with DSM-IV panic disorder." | 9.12 | The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. ( Raj, BA; Sheehan, DV; Sheehan, KH, 2007) |
| "In 123 panic disorder patients undergoing gradual tapered discontinuation of alprazolam in conjunction with pre-treatment with carbamazepine or placebo, the relationship between measures of 'symptom sensitivity' and 'harm avoidance', and severity of withdrawal symptoms measured as peak severity of symptoms, time before taper needed to be slowed due to symptoms, and ability to complete taper, was examined." | 9.10 | Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. ( Ballenger, J; Bell, J; Bystrisky, A; Corrigan, MH; Pollack, M; Rosenbaum, J; Roy-Byrne, P; Rush, AJ; Russo, J; Stewart, R; Stolk, J, 2003) |
| " Results showed that 75% of the Peoria sample and 76% of the Dartmouth sample were able to discontinue alprazolam therapy, remain abstinent of any type of treatment for panic disorder, and maintain their acute-treatment clinical gains over this follow-up period." | 9.09 | Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. ( Bruce, TJ; Hegel, MT; Spiegel, DA, 1999) |
| " A previous study with agoraphobia/panic patients found that the BZ alprazolam impaired memory during an 8-week treatment and residual impairments were still manifest several weeks after drug withdrawal (Curran et al." | 9.09 | Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients. ( Başoğlu, M; Curran, HV; Kiliç, C; Marks, IM; Noshirvani, H, 1999) |
| "Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder." | 9.09 | Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. ( Sheikh, JI; Swales, PJ, 1999) |
| "The pharmacokinetics and pharmacodynamics of the benzodiazepine alprazolam (1 mg, administered orally) were compared between eight patients with panic disorder and eight age- and sex-matched healthy volunteers." | 9.09 | Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. ( Ehrenberg, BL; Goddard, JE; Greenblatt, DJ; Harmatz, JS; Kaplan, GB; Shader, RI, 2000) |
| " As part of a placebo-controlled trial of alprazolam-XR (extended release) administered in combination with cognitive-behavioral therapy in patients with panic disorder, a battery of tests was used to measure neuropsychologic function." | 9.09 | Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. ( Auerbach, M; Gladsjo, JA; Hahn, T; Haze, A; Judd, LL; McKinney, R; Oliver, T; Rabin, A; Rapaport, MH, 2001) |
| ") and to clonidine (150 micrograms) were measured in 10 outpatients with panic disorder before and after 30 days of 2-2." | 9.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. ( Bellodi, L; Brambilla, F; Garberi, A; Nobile, P; Perna, G, 1995) |
| "The cortisol responses to acute administration of saline and of clonidine (Clon), 150 micrograms IV, were examined in 12 patients with panic disorder and agoraphobia, before and after 32 days of alprazolam therapy (2." | 9.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. ( Arancio, C; Bellodi, L; Brambilla, F; Nobile, P; Perna, G, 1995) |
| "22 patients with panic disorder (diagnosis according to ICD-10) were treated with alprazolam (monotherapy) in a dose of 1-2,5 mg/daily during 6 weeks." | 9.08 | [The efficacy of alprazolam in the therapy of panic disorders]. ( Diukova, GM; Petrova, EP; Smirnov, SV; Tumalaeva, ZN; Vorob'eva, OV, 1995) |
| "Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients." | 9.08 | Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. ( Halonen, T; Jolkkonen, J; Lepola, U; Riekkinen, P; Rimón, R, 1995) |
| "23 patients with a diagnosis of panic disorder with agoraphobia were randomly assigned to 8 weeks' treatment with alprazolam or placebo." | 9.08 | Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. ( Bond, AJ; Bruce, MS; Curran, HV; O'Sullivan, G; Shine, P, 1995) |
| "Alprazolam has proven efficacy as a treatment for panic disorder, but the place of other benzodiazepines is less well established." | 9.08 | Diazepam versus alprazolam for the treatment of panic disorder. ( Burrows, GD; Cook, BL; Garvey, MJ; Judd, FK; Marriott, P; Norman, TR; Noyes, R; Reich, JH, 1996) |
| " The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured." | 9.07 | Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. ( Başoğlu, M; Kirby, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, GH; Swinson, R, 1994) |
| " Eighty-two agoraphobics with panic disorder were randomly allocated to one of four treatment groups resulting from a combination of two drug treatments (alprazolam or placebo) and two psychological treatments (exposure or relaxation)." | 9.07 | Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. ( Bond, A; Bruce, M; Curran, HV; Lader, M; Lelliot, P; Marks, I; O'Sullivan, G; Shine, P, 1994) |
| "Pre-treatment predictors of treatment outcome were examined in a group of 144 patients with panic disorder and agoraphobia randomly allocated to alprazolam+exposure (AE), placebo+exposure (PE), alprazolam+relaxation (AR), and placebo+relaxation (PR)." | 9.07 | Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "In a controlled trial of alprazolam and exposure in 154 patients with panic disorder with agoraphobia, relations between panic, anticipatory anxiety, and phobic avoidance were examined." | 9.07 | Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kiliç, C; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "Patients with panic disorder plus agoraphobia had 8 weeks of drug treatment (alprazolam or placebo) plus psychological treatment (exposure or relaxation)." | 9.07 | Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. ( Başoğlu, M; Brewin, CR; Kiliç, C; Marks, IM; Swinson, RP, 1994) |
| "This study was designed to examine the possibility that patients with panic disorder are especially vulnerable to alprazolam withdrawal, as well as to evaluate the efficacy of carbamazepine as adjunctive treatment during alprazolam discontinuation." | 9.07 | Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. ( Colin, V; Klein, E; Lenox, RH; Stolk, J, 1994) |
| "This study examines clinical predictors of outcome for patients with panic disorder and depression in a 16 week, placebo-controlled trial of alprazolam and imipramine (n = 126)." | 9.07 | Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. ( Deltito, JA; Keller, MB; Leon, A; Otto, MW; Pollack, MH; Rosenbaum, JF; Sachs, GS; Shear, MK, 1994) |
| "The primary aim of this study was to determine if pretreatment with a single dose of alprazolam reduces anxiety and panic provoked by the inhalation of 35% carbon dioxide (CO2) in patients with panic disorder." | 9.07 | Alprazolam blockade of CO2-provoked panic in patients with panic disorder. ( Asnis, GM; Sanderson, WC; Wetzler, S, 1994) |
| "Date from a panic disorder treatment study with 506 patients, comparing alprazolam and placebo in a double-blind manner for 8 weeks, were analyzed to identify demographic and clinical characteristics of the patients that might predict response to treatment." | 9.07 | Predictors of response to alprazolam and placebo in patients with panic disorder. ( Ballenger, JC; Lydiard, RB; Mihalko, D; Noyes, R; Sievers, G; Woodman, CL, 1994) |
| "The authors investigated whether cognitive behavioral treatment could facilitate discontinuation of alprazolam therapy and maintenance of drug abstinence among panic disorder patients treated with alprazolam doses sufficient to suppress spontaneous panic attacks." | 9.07 | Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? ( Bruce, TJ; Gregg, SF; Nuzzarello, A; Spiegel, DA, 1994) |
| "One hundred ninety-four patients with diagnosis of agoraphobia with panic attacks or panic disorder with limited phobic avoidance underwent a 1-week placebo washout before being randomly assigned to groups receiving 8 weeks of double-blind treatment with either sustained-release alprazolam or placebo." | 9.07 | Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. ( Patterson, W; Rickels, K; Rosenthal, M; Schweizer, E, 1993) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 9.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "A series of 237 patients with DSM-III-diagnosed panic disorder, or agoraphobia with panic attacks, received alprazolam as part of the placebo-controlled Cross-National Collaborative Panic Study." | 9.07 | Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. ( Greenblatt, DJ; Harmatz, JS; Shader, RI, 1993) |
| " According to logistic regression analysis, the relationships between plasma alprazolam concentration and response, as reflected by number of panic attacks reported, phobia ratings, physicians' and patients' ratings of global improvement, and the emergence of side effects, were significant." | 9.07 | Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. ( Antal, E; Ballenger, JC; DuPont, R; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "The reactivity of 40 panic disorder patients on mental arithmetic, cold pressor, and 5% CO2 inhalation stressors was tested before and after 8 weeks of treatment with imipramine, alprazolam, or placebo." | 9.07 | Imipramine and alprazolam effects on stress test reactivity in panic disorder. ( Agras, WS; Ehlers, A; Haddad, JM; Maddock, RJ; Margraf, J; Roth, WT; Taylor, CB, 1992) |
| "To investigate whether alprazolam (ALP) coprescription early in the imipramine (IMI) treatment of panic disorder would improve overall treatment response to IMI alone, 48 panic disorder patients were randomly assigned to receive either IMI plus placebo or IMI plus ALP for 4-6 weeks, followed by 2 weeks of IMI plus placebo-ALP taper and 2 more weeks of IMI alone." | 9.07 | Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. ( Charney, DS; Heninger, GR; Koleszar, AS; Krystal, JH; Nagy, LM; Woods, SW, 1992) |
| "A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam." | 9.07 | A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. ( Ballenger, JC; DuPont, R; Laraia, M; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature." | 8.88 | The role of alprazolam for the treatment of panic disorder in Australia. ( Berk, M; Giorlando, F; Moylan, S; Nordfjærn, T, 2012) |
| "We performed a meta-analysis of all single- or double-blind, randomized controlled trials comparing alprazolam to another benzodiazepine in the treatment of adult patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Third or Fourth Edition, criteria for panic disorder or agoraphobia with panic attacks." | 8.87 | The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. ( Berk, M; Moylan, S; Rogerson, J; Staples, J; Stein, DJ; Ward, SA, 2011) |
| "Alprazolam was the first pharmacological agent to be approved for the treatment of panic disorder." | 8.80 | Efficacy studies of alprazolam in panic disorder. ( Spiegel, DA, 1998) |
| " Doxapram is an analeptic capable of inducing panic attacks with respiratory symptoms in individuals diagnosed with the disorder; however, its neuroanatomical targets and its effects on experimental animals remain uncharacterized." | 8.02 | Intravenous doxapram administration as a potential model of panic attacks in rats. ( Batista, LA; Brianis, RC; Haibara, AS; Lopes, JB; Moreira, FA, 2021) |
| "We experienced an 11-year-old boy with panic disorder responding remarkably to paroxetine." | 7.74 | 11-year-old boy with panic disorder responding to paroxetine. ( Matsumoto, H; Tamai, Y, 2007) |
| "This study investigated an anxiety-prone cognitive style (measured by the Anxious Thoughts and Tendencies Questionnaire, AT&T) as a predictor of the acute response to increasing alprazolam plasma levels in panic disorder." | 7.74 | Cognitive style, alprazolam plasma levels, and treatment response in panic disorder. ( Antal, EJ; Barnhill, J; Javaid, JI; Matuzas, W; Qualls, C; Starcevic, V; Uhlenhuth, EH, 2008) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 7.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| " Changes in the plasma cortisol level were reported in a male patient with panic disorder during the period of low-dose alprazolam treatment (mean 0." | 7.70 | Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report. ( Fukuda, M; Hata, A; Hiramatsu, K; Iwanami, A; Kasai, K; Nakagome, K; Takazawa, S, 1998) |
| "Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) were measured in 10 outpatients with panic disorder, twice (at a 48-h interval) before and twice on days 30-32 of treatment with alprazolam (2-2." | 7.70 | Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. ( Bellodi, L; Brambilla, F; Perna, G, 1999) |
| "In a previous paper the authors reported survival data for 20 panic disorder patients whose therapeutic doses of alprazolam were tapered by one of two methods: slow, flexible drug taper with supportive medical management or the same taper procedure carried out concurrently with cognitive behavior therapy." | 7.69 | Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. ( Bruce, TJ; Gregg, SF; Nuzzarello, A; Spiegel, DA, 1995) |
| "The aim of the current study was to determine the degree to which patients with panic disorder develop tolerance to subjective and physiological effects of benzodiazepine after chronic treatment with alprazolam." | 7.69 | Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. ( Cowley, DS; Greenblatt, DJ; Hommer, DW; Nemeroff, CB; Radant, A; Ritchie, JC; Roy-Byrne, PP, 1995) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 7.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Thirty-six patients with panic disorder (PD) and 35 patients with generalized anxiety disorder (GAD) participated in an open alprazolam treatment phase that preceded controlled withdrawal from alprazolam." | 7.69 | Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. ( Colin, V; Greenberg, A; Klein, E; Lenox, RH; Levy, N; Zilberman, I; Zinder, O, 1995) |
| "This study applied the corticotropin-releasing hormone (CRH) stimulation test to patients with panic disorder, before and during treatment with alprazolam, and to control subjects." | 7.69 | Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. ( Abelson, JL; Curtis, GC; Gold, PW, 1997) |
| "Out of 69 patients with panic disorder plus agoraphobia who had been in an 8-week controlled study of alprazolam and/or exposure, 31 were followed up at a mean of 3." | 7.69 | Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. ( Başoğlu, M; Kiliç, C; Marks, I; Noshirvani, H, 1997) |
| "This 8-week double-blind placebo-controlled trial investigated the relative efficacy and safety of alprazolam and buspirone in the treatment of panic disorder." | 7.68 | The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. ( Harnett-Sheehan, K; Knapp, E; Raj, AB; Sheehan, DV; Soto, S, 1993) |
| " The charts of 78 panic disorder outpatients treated with alprazolam (mean dose 4." | 7.68 | Alprazolam in panic disorder: a retrospective analysis. ( Harvey, DS; Loosen, PT; Shelton, RC; Stewart, PM, 1993) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 7.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| "Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing." | 6.71 | Alprazolam extended-release in panic disorder. ( Rickels, K, 2004) |
| " The aim of the XR preparation is to offer less frequent dosing and to reduce interdose anxiety." | 6.67 | A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. ( Alexander, P; Luthe, L; Munjack, D; Pecknold, J, 1994) |
| "Panic disorder is a chronic illness with only some degree of spontaneous recovery." | 6.67 | Discontinuation reactions to alprazolam in panic disorder. ( Pecknold, JC, 1993) |
| " If a side effect profile is known, it will be easier for a clinician to choose the right drug and the appropriate management by taking into account compliance, safety and efficacy in each patient under treatment." | 6.67 | Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. ( Benkert, O; Cassano, GB; Curtis, G; Deltito, J; Hippius, H; Klerman, G; Maier, W; Petracca, A; Shera, D; Toni, C, 1994) |
| "5 years, 78% of patients remained on medication and the mean dosage of alprazolam and clonazepam did not increase." | 6.67 | Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. ( Cohen, LS; Meltzer-Brody, S; Otto, MW; Pollack, MH; Rosenbaum, JF; Tesar, GE, 1993) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 6.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "The etiology and optimum treatment of panic disorder remain unclear." | 6.39 | Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. ( Boyer, W, 1995) |
| "Posttraumatic stress disorder (PTSD) and panic disorder (PD) share several clinical features, and theory postulates that phasic arousal is similarly dysregulated in both." | 5.30 | Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder. ( Bloch, M; Bonne, O; Peri, T; Shalev, AY, 1998) |
| " Here, we found that the translocator protein (18 kD) ligand XBD173 enhanced gamma-aminobutyric acid-mediated neurotransmission and counteracted induced panic attacks in rodents in the absence of sedation and tolerance development." | 5.14 | Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. ( Baghai, TC; Bertaina-Anglade, V; Chaperon, F; Eser, D; Floesser, A; Gentsch, C; Holsboer, F; Kalkman, HO; Kiese, B; Kucher, K; La Rochelle, CD; Landgraf, R; McAllister, KH; Nothdurfter, C; Rammes, G; Rupprecht, R; Schüle, C; Schumacher, M; Troxler, T; Tuerck, D; Uzunov, V, 2009) |
| "The objective of this study was to ascertain the relationship of alprazolam plasma levels and an anxiety-prone cognitive style to the characteristics and severity of early withdrawal after abrupt discontinuation of alprazolam in 26 patients with panic disorder." | 5.12 | Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. ( Antal, EJ; Barnhill, J; Javaid, JI; Matuzas, W; Qualls, C; Starcevic, V; Uhlenhuth, EH, 2006) |
| "Anxiolytic therapy with the benzodiazepine alprazolam is an established therapy in patients with panic disorder." | 5.12 | Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders. ( Béchir, M; Binggeli, C; Büchi, S; Buddeberg, C; Caduff, C; Chenevard, R; Lüscher, TF; Noll, G; Schwegler, K, 2007) |
| "This study compares the speed of onset of action of the extended release (XR) formulation of alprazolam with that of the compressed tablet (CT) formulation in a sample of outpatients with DSM-IV panic disorder." | 5.12 | The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. ( Raj, BA; Sheehan, DV; Sheehan, KH, 2007) |
| "A compared, 12 week, placebo controlled study, with fixed dose, outpatient study of patients diagnosed with panic disorder with and without agoraphobia according to ICD-10, was conducted to evaluate the efficacy and safety of sertraline and alprazolam." | 5.11 | Sertraline and alprazolam in the treatment of panic desorder. ( Fiseković, S; Loga-Zec, S, 2005) |
| "In 123 panic disorder patients undergoing gradual tapered discontinuation of alprazolam in conjunction with pre-treatment with carbamazepine or placebo, the relationship between measures of 'symptom sensitivity' and 'harm avoidance', and severity of withdrawal symptoms measured as peak severity of symptoms, time before taper needed to be slowed due to symptoms, and ability to complete taper, was examined." | 5.10 | Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. ( Ballenger, J; Bell, J; Bystrisky, A; Corrigan, MH; Pollack, M; Rosenbaum, J; Roy-Byrne, P; Rush, AJ; Russo, J; Stewart, R; Stolk, J, 2003) |
| " Results showed that 75% of the Peoria sample and 76% of the Dartmouth sample were able to discontinue alprazolam therapy, remain abstinent of any type of treatment for panic disorder, and maintain their acute-treatment clinical gains over this follow-up period." | 5.09 | Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. ( Bruce, TJ; Hegel, MT; Spiegel, DA, 1999) |
| " A previous study with agoraphobia/panic patients found that the BZ alprazolam impaired memory during an 8-week treatment and residual impairments were still manifest several weeks after drug withdrawal (Curran et al." | 5.09 | Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients. ( Başoğlu, M; Curran, HV; Kiliç, C; Marks, IM; Noshirvani, H, 1999) |
| "Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder." | 5.09 | Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. ( Sheikh, JI; Swales, PJ, 1999) |
| "The pharmacokinetics and pharmacodynamics of the benzodiazepine alprazolam (1 mg, administered orally) were compared between eight patients with panic disorder and eight age- and sex-matched healthy volunteers." | 5.09 | Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. ( Ehrenberg, BL; Goddard, JE; Greenblatt, DJ; Harmatz, JS; Kaplan, GB; Shader, RI, 2000) |
| " As part of a placebo-controlled trial of alprazolam-XR (extended release) administered in combination with cognitive-behavioral therapy in patients with panic disorder, a battery of tests was used to measure neuropsychologic function." | 5.09 | Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. ( Auerbach, M; Gladsjo, JA; Hahn, T; Haze, A; Judd, LL; McKinney, R; Oliver, T; Rabin, A; Rapaport, MH, 2001) |
| ") and to clonidine (150 micrograms) were measured in 10 outpatients with panic disorder before and after 30 days of 2-2." | 5.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. ( Bellodi, L; Brambilla, F; Garberi, A; Nobile, P; Perna, G, 1995) |
| "The cortisol responses to acute administration of saline and of clonidine (Clon), 150 micrograms IV, were examined in 12 patients with panic disorder and agoraphobia, before and after 32 days of alprazolam therapy (2." | 5.08 | Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. ( Arancio, C; Bellodi, L; Brambilla, F; Nobile, P; Perna, G, 1995) |
| "22 patients with panic disorder (diagnosis according to ICD-10) were treated with alprazolam (monotherapy) in a dose of 1-2,5 mg/daily during 6 weeks." | 5.08 | [The efficacy of alprazolam in the therapy of panic disorders]. ( Diukova, GM; Petrova, EP; Smirnov, SV; Tumalaeva, ZN; Vorob'eva, OV, 1995) |
| "Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients." | 5.08 | Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. ( Halonen, T; Jolkkonen, J; Lepola, U; Riekkinen, P; Rimón, R, 1995) |
| "23 patients with a diagnosis of panic disorder with agoraphobia were randomly assigned to 8 weeks' treatment with alprazolam or placebo." | 5.08 | Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. ( Bond, AJ; Bruce, MS; Curran, HV; O'Sullivan, G; Shine, P, 1995) |
| "Alprazolam has proven efficacy as a treatment for panic disorder, but the place of other benzodiazepines is less well established." | 5.08 | Diazepam versus alprazolam for the treatment of panic disorder. ( Burrows, GD; Cook, BL; Garvey, MJ; Judd, FK; Marriott, P; Norman, TR; Noyes, R; Reich, JH, 1996) |
| "A group of 20 patients who met the DSM-III-R criteria for panic disorder with or without agoraphobia underwent a 35% carbon dioxide (CO2) challenge after either 1 mg alprazolam or placebo in a double-blind, randomized, cross-over design." | 5.08 | Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients. ( Griez, E; Hauzer, R; Meijer, J; Pols, H; Verburg, K, 1996) |
| " We reanalyzed a study of 81 panic patients treated with placebo, alprazolam 2 mg or 6 mg, or imipramine 225 mg daily to investigate the effect of baseline pathology and selective effects of treatment on biological and cognitive components of panic disorder." | 5.08 | Growing placebo response rate: the problem in recent therapeutic trials? ( Matuzas, W; Thompson, PM; Uhlenhuth, EH; Warner, TD, 1997) |
| "The reinforcing effects of alprazolam were investigated in 14 patients who had generalized anxiety or panic disorder, but were not current users/abusers of other psychoactive substances." | 5.08 | Alprazolam-reinforced medication use in outpatients with anxiety. ( Creson, DR; Meisch, RA; Roache, JD; Shah, NN; Stanley, MA, 1997) |
| "We determined whether blindness in a double-blind randomized controlled trial of alprazolam and exposure therapies in patients with panic disorder and agoraphobia was maintained in assessors and patients, what were the factors related to "unblinding," and whether unblinding was associated with clinical outcome." | 5.08 | Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. ( Başoğlu, M; Livanou, M; Marks, I; Swinson, R, 1997) |
| "Fifty-two subjects with panic disorder and generalized anxiety disorder were interviewed 12-18 months after they completed an acute treatment study (9-11 weeks) with alprazolam followed by blind and controlled drug discontinuation." | 5.08 | Subjective experience and attitudes towards participation in clinical trials among patients with anxiety disorders. ( Klein, E; Lenox, RH; Malel, D; Zilberman, I, 1997) |
| " The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured." | 5.07 | Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. ( Başoğlu, M; Kirby, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, GH; Swinson, R, 1994) |
| " Eighty-two agoraphobics with panic disorder were randomly allocated to one of four treatment groups resulting from a combination of two drug treatments (alprazolam or placebo) and two psychological treatments (exposure or relaxation)." | 5.07 | Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. ( Bond, A; Bruce, M; Curran, HV; Lader, M; Lelliot, P; Marks, I; O'Sullivan, G; Shine, P, 1994) |
| "Pre-treatment predictors of treatment outcome were examined in a group of 144 patients with panic disorder and agoraphobia randomly allocated to alprazolam+exposure (AE), placebo+exposure (PE), alprazolam+relaxation (AR), and placebo+relaxation (PR)." | 5.07 | Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "In a controlled trial of alprazolam and exposure in 154 patients with panic disorder with agoraphobia, relations between panic, anticipatory anxiety, and phobic avoidance were examined." | 5.07 | Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure. ( Başoğlu, M; Kiliç, C; Kuch, K; Marks, IM; Noshirvani, H; O'Sullivan, G; Swinson, RP, 1994) |
| "Patients with panic disorder plus agoraphobia had 8 weeks of drug treatment (alprazolam or placebo) plus psychological treatment (exposure or relaxation)." | 5.07 | Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. ( Başoğlu, M; Brewin, CR; Kiliç, C; Marks, IM; Swinson, RP, 1994) |
| "Forty Danish panic disorder patients participating in a placebo controlled study of alprazolam and imipramine (The Cross National Collaborative Panic Study, Phase II) were followed up by a telephone interview three years later, with essentially the same battery of evaluation procedures applied at baseline, end of study, and follow-up." | 5.07 | Three years follow-up of panic disorder patients: a naturalistic study. ( Rosenberg, NK; Rosenberg, R, 1994) |
| "This study was designed to examine the possibility that patients with panic disorder are especially vulnerable to alprazolam withdrawal, as well as to evaluate the efficacy of carbamazepine as adjunctive treatment during alprazolam discontinuation." | 5.07 | Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. ( Colin, V; Klein, E; Lenox, RH; Stolk, J, 1994) |
| "This study examines clinical predictors of outcome for patients with panic disorder and depression in a 16 week, placebo-controlled trial of alprazolam and imipramine (n = 126)." | 5.07 | Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. ( Deltito, JA; Keller, MB; Leon, A; Otto, MW; Pollack, MH; Rosenbaum, JF; Sachs, GS; Shear, MK, 1994) |
| "The primary aim of this study was to determine if pretreatment with a single dose of alprazolam reduces anxiety and panic provoked by the inhalation of 35% carbon dioxide (CO2) in patients with panic disorder." | 5.07 | Alprazolam blockade of CO2-provoked panic in patients with panic disorder. ( Asnis, GM; Sanderson, WC; Wetzler, S, 1994) |
| " The group with prominent respiratory symptoms suffered more spontaneous panic attacks and responded to imipramine, whereas the group without prominent respiratory symptoms suffered more situational panic attacks and responded more to alprazolam." | 5.07 | Subtyping of panic disorder by symptom profile. ( Brandon, S; Briggs, AC; Stretch, DD, 1993) |
| " The present study provided systematic data from a double blind comparison of maintenance therapy (up to 8 months) of panic disorder with or without agoraphobia with alprazolam, imipramine, or placebo in 181 patients who had responded to the same regimen in a randomized 8-week treatment trial." | 5.07 | Maintenance drug therapy of panic disorder. ( Ayuso, JL; Cassano, GB; Curtis, GC; Massana, J; Perugi, G; Udina, C, 1993) |
| "Date from a panic disorder treatment study with 506 patients, comparing alprazolam and placebo in a double-blind manner for 8 weeks, were analyzed to identify demographic and clinical characteristics of the patients that might predict response to treatment." | 5.07 | Predictors of response to alprazolam and placebo in patients with panic disorder. ( Ballenger, JC; Lydiard, RB; Mihalko, D; Noyes, R; Sievers, G; Woodman, CL, 1994) |
| "The authors investigated whether cognitive behavioral treatment could facilitate discontinuation of alprazolam therapy and maintenance of drug abstinence among panic disorder patients treated with alprazolam doses sufficient to suppress spontaneous panic attacks." | 5.07 | Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? ( Bruce, TJ; Gregg, SF; Nuzzarello, A; Spiegel, DA, 1994) |
| "One hundred ninety-four patients with diagnosis of agoraphobia with panic attacks or panic disorder with limited phobic avoidance underwent a 1-week placebo washout before being randomly assigned to groups receiving 8 weeks of double-blind treatment with either sustained-release alprazolam or placebo." | 5.07 | Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. ( Patterson, W; Rickels, K; Rosenthal, M; Schweizer, E, 1993) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 5.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "A series of 237 patients with DSM-III-diagnosed panic disorder, or agoraphobia with panic attacks, received alprazolam as part of the placebo-controlled Cross-National Collaborative Panic Study." | 5.07 | Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. ( Greenblatt, DJ; Harmatz, JS; Shader, RI, 1993) |
| "Outpatients treated for panic disorder with alprazolam or clonazepam for a minimum of 6 months and expressing a desire to stop taking the medication (N = 33) were randomly assigned to one of two taper conditions: a slow taper condition alone or a slow taper condition in conjunction with 10 weeks of group cognitive-behavioral therapy." | 5.07 | Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. ( Meltzer-Brody, S; Otto, MW; Pollack, MH; Reiter, SR; Rosenbaum, JF; Sachs, GS, 1993) |
| "Forty-eight patients with panic disorder completing 8 months of maintenance treatment with alprazolam (mean dose, 5." | 5.07 | Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "The present study is aimed at assessing a 48-outpatient sample that had been diagnosed as Panic Disorder cases: Approximately 5 years ago, patients had been treated with either Alprazolam, Imipramine or placebo during an 8-week double-blind trial." | 5.07 | [Patients with panic disorder: a 5-year follow-up study]. ( Arévalo, W; Gaviria, LF; Leon, A; León, CA, 1992) |
| "The acute effects of diazepam on plasma GABA were determined in 18 patients with panic disorder, 13 patients with generalized anxiety disorder and 20 healthy controls." | 5.07 | Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. ( Cowley, DS; Greenblatt, DJ; Hommer, D; Kramer, GL; Petty, F; Roy-Byrne, PP, 1992) |
| " According to logistic regression analysis, the relationships between plasma alprazolam concentration and response, as reflected by number of panic attacks reported, phobia ratings, physicians' and patients' ratings of global improvement, and the emergence of side effects, were significant." | 5.07 | Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. ( Antal, E; Ballenger, JC; DuPont, R; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "The reactivity of 40 panic disorder patients on mental arithmetic, cold pressor, and 5% CO2 inhalation stressors was tested before and after 8 weeks of treatment with imipramine, alprazolam, or placebo." | 5.07 | Imipramine and alprazolam effects on stress test reactivity in panic disorder. ( Agras, WS; Ehlers, A; Haddad, JM; Maddock, RJ; Margraf, J; Roth, WT; Taylor, CB, 1992) |
| "To investigate whether alprazolam (ALP) coprescription early in the imipramine (IMI) treatment of panic disorder would improve overall treatment response to IMI alone, 48 panic disorder patients were randomly assigned to receive either IMI plus placebo or IMI plus ALP for 4-6 weeks, followed by 2 weeks of IMI plus placebo-ALP taper and 2 more weeks of IMI alone." | 5.07 | Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. ( Charney, DS; Heninger, GR; Koleszar, AS; Krystal, JH; Nagy, LM; Woods, SW, 1992) |
| "A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam." | 5.07 | A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. ( Ballenger, JC; DuPont, R; Laraia, M; Lesser, IM; Lydiard, RB; Rubin, RT, 1992) |
| "We studied the efficacy of propranolol (Inderal) compared to alprazolam (Xanax) in 29 patients with a diagnosis of agoraphobia with panic disorder or panic disorder with or without limited phobic avoidance in a 6-week double-blind controlled experiment." | 5.07 | A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. ( Friedman, MJ; Hauri, PJ; McHugo, GJ; Ravaris, CL, 1991) |
| "The impact of the avoidance behaviour on the psychopharmacological treatment of panic disorder was explored in the Cross National Collaborative Panic Study (n = 1134 patients); in this double blind randomized trial alprazolam, imipramine and placebo were compared during an 8-week treatment period." | 5.07 | Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? ( Argyle, N; Benkert, O; Brandon, S; Buller, R; Lavori, P; Maier, W; Roth, SM, 1991) |
| "To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature." | 4.88 | The role of alprazolam for the treatment of panic disorder in Australia. ( Berk, M; Giorlando, F; Moylan, S; Nordfjærn, T, 2012) |
| "We performed a meta-analysis of all single- or double-blind, randomized controlled trials comparing alprazolam to another benzodiazepine in the treatment of adult patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Third or Fourth Edition, criteria for panic disorder or agoraphobia with panic attacks." | 4.87 | The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. ( Berk, M; Moylan, S; Rogerson, J; Staples, J; Stein, DJ; Ward, SA, 2011) |
| "Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression." | 4.82 | Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature. ( Verster, JC; Volkerts, ER, 2004) |
| "Alprazolam was the first pharmacological agent to be approved for the treatment of panic disorder." | 4.80 | Efficacy studies of alprazolam in panic disorder. ( Spiegel, DA, 1998) |
| "A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant medications)." | 4.78 | A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. ( Cohon, MS; Jonas, JM, 1993) |
| "Therapeutic efficacy for depression and panic disorder has been demonstrated with the triazolobenzodiazepine alprazolam." | 4.78 | Alprazolam and depression: a review of risks and benefits. ( Fawcett, J; Kravitz, HM; Newman, AJ, 1993) |
| " Doxapram is an analeptic capable of inducing panic attacks with respiratory symptoms in individuals diagnosed with the disorder; however, its neuroanatomical targets and its effects on experimental animals remain uncharacterized." | 4.02 | Intravenous doxapram administration as a potential model of panic attacks in rats. ( Batista, LA; Brianis, RC; Haibara, AS; Lopes, JB; Moreira, FA, 2021) |
| " Previously, she was treated for a longer period with alprazolam due to panic disorder." | 3.80 | Pseudopheochromocytoma induced by anxiolytic withdrawal. ( Barna, S; Becs, G; Czifra, A; Erdei, A; Kovács, P; Páll, A; Páll, D; Paragh, G; Pfliegler, G; Sira, L; Szabó, Z, 2014) |
| ") sodium lactate (NaLac) infusions, in a manner similar to what occurs in patients with panic disorder." | 3.79 | Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats. ( Engleman, EA; Fitz, SD; Johnson, PL; Schkeryantz, JM; Shekhar, A; Svensson, KA, 2013) |
| "We experienced an 11-year-old boy with panic disorder responding remarkably to paroxetine." | 3.74 | 11-year-old boy with panic disorder responding to paroxetine. ( Matsumoto, H; Tamai, Y, 2007) |
| "This study investigated an anxiety-prone cognitive style (measured by the Anxious Thoughts and Tendencies Questionnaire, AT&T) as a predictor of the acute response to increasing alprazolam plasma levels in panic disorder." | 3.74 | Cognitive style, alprazolam plasma levels, and treatment response in panic disorder. ( Antal, EJ; Barnhill, J; Javaid, JI; Matuzas, W; Qualls, C; Starcevic, V; Uhlenhuth, EH, 2008) |
| "Escitalopram, the active enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, has effects in animal models for the detection of antidepressant and anxiolytic effect and in patients with major depressive and anxiety disorders." | 3.73 | Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. ( Hogg, S; Jessa, M; Michan, L, 2006) |
| " Changes in the plasma cortisol level were reported in a male patient with panic disorder during the period of low-dose alprazolam treatment (mean 0." | 3.70 | Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report. ( Fukuda, M; Hata, A; Hiramatsu, K; Iwanami, A; Kasai, K; Nakagome, K; Takazawa, S, 1998) |
| "Plasma concentrations of tumor necrosis factor-alpha (TNF-alpha) were measured in 10 outpatients with panic disorder, twice (at a 48-h interval) before and twice on days 30-32 of treatment with alprazolam (2-2." | 3.70 | Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. ( Bellodi, L; Brambilla, F; Perna, G, 1999) |
| "In a previous paper the authors reported survival data for 20 panic disorder patients whose therapeutic doses of alprazolam were tapered by one of two methods: slow, flexible drug taper with supportive medical management or the same taper procedure carried out concurrently with cognitive behavior therapy." | 3.69 | Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. ( Bruce, TJ; Gregg, SF; Nuzzarello, A; Spiegel, DA, 1995) |
| "Plasma interleukin-1 beta (IL-1 beta) concentrations were measured in 10 outpatients with panic disorder before and on days 30 and 32 of treatment with alprazolam (2-2." | 3.69 | Plasma interleukin-1 beta concentrations in panic disorder. ( Bellodi, L; Bertani, A; Brambilla, F; Panerai, A; Perna, G; Sacerdote, P, 1994) |
| "The aim of the current study was to determine the degree to which patients with panic disorder develop tolerance to subjective and physiological effects of benzodiazepine after chronic treatment with alprazolam." | 3.69 | Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. ( Cowley, DS; Greenblatt, DJ; Hommer, DW; Nemeroff, CB; Radant, A; Ritchie, JC; Roy-Byrne, PP, 1995) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 3.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "Follow-up clinical data were obtained for 18 of 20 patients with panic disorder who participated in a detailed study of HPA axis activity in panic, both before and during their treatment with alprazolam." | 3.69 | Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. ( Abelson, JL; Curtis, GC, 1996) |
| "Thirty-six patients with panic disorder (PD) and 35 patients with generalized anxiety disorder (GAD) participated in an open alprazolam treatment phase that preceded controlled withdrawal from alprazolam." | 3.69 | Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. ( Colin, V; Greenberg, A; Klein, E; Lenox, RH; Levy, N; Zilberman, I; Zinder, O, 1995) |
| "This study applied the corticotropin-releasing hormone (CRH) stimulation test to patients with panic disorder, before and during treatment with alprazolam, and to control subjects." | 3.69 | Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. ( Abelson, JL; Curtis, GC; Gold, PW, 1997) |
| "Out of 69 patients with panic disorder plus agoraphobia who had been in an 8-week controlled study of alprazolam and/or exposure, 31 were followed up at a mean of 3." | 3.69 | Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment. ( Başoğlu, M; Kiliç, C; Marks, I; Noshirvani, H, 1997) |
| "This 8-week double-blind placebo-controlled trial investigated the relative efficacy and safety of alprazolam and buspirone in the treatment of panic disorder." | 3.68 | The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. ( Harnett-Sheehan, K; Knapp, E; Raj, AB; Sheehan, DV; Soto, S, 1993) |
| " The charts of 78 panic disorder outpatients treated with alprazolam (mean dose 4." | 3.68 | Alprazolam in panic disorder: a retrospective analysis. ( Harvey, DS; Loosen, PT; Shelton, RC; Stewart, PM, 1993) |
| "Immunological, neuroendocrine and psychological parameters were examined in 14 psychophysically healthy subjects and in 17 panic disorder patients before and after a 30-day course of alprazolam therapy." | 3.68 | Psychoimmunoendocrine aspects of panic disorder. ( Battaglia, M; Bellodi, L; Brambilla, F; Diaferia, G; Panerai, A; Perna, G; Petraglia, F; Sacerdote, P; Sciuto, G, 1992) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 3.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| "Alprazolam and diazepam were associated with a lower dropout rate compared to placebo and were ranked as the most tolerated of all the medications examined." | 3.01 | Pharmacological treatments in panic disorder in adults: a network meta-analysis. ( Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A, 2023) |
| "Despite its acute efficacy for the treatment of panic disorder, benzodiazepines (BZs) are associated with a withdrawal syndrome that closely mimics anxiety sensations, leading to difficulty with treatment discontinuation and often disorder relapse." | 2.75 | Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. ( Farach, FJ; McHugh, RK; Otto, MW; Pollack, MH; Simon, NM; Worthington, JJ, 2010) |
| "Alprazolam-XR is an extended-release formulation of alprazolam designed to deliver sustained therapeutic concentrations for 24 h after once-daily dosing." | 2.71 | Alprazolam extended-release in panic disorder. ( Rickels, K, 2004) |
| "Patients with panic disorder have blunted growth hormone (GH) responses to clonidine, suggesting subsensitivity of post-synaptic alpha(2)-adrenoreceptors, presumably in response to excessive central noradrenergic outflow." | 2.71 | Twenty-four hour growth hormone secretion in patients with panic disorder. ( Abelson, JL; Curtis, GC; Uhde, TW, 2005) |
| "Alprazolam clearly was preferred over placebo; however, there were large between-subjects differences in the amount of medication used." | 2.69 | Predictors of individual differences in alprazolam self-medication. ( Oswald, LM; Rhoades, HM; Roache, JD, 1999) |
| "The course of panic disorder is not uniform." | 2.68 | Long-term follow-up after a drug trial for panic disorder. ( Amering, M; Ballenger, JC; Briggs, A; Buller, R; Cassano, G; Garvey, M; Katschnig, H; Klerman, GL; Roth, M; Stolk, JM, 1995) |
| " The aim of the XR preparation is to offer less frequent dosing and to reduce interdose anxiety." | 2.67 | A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. ( Alexander, P; Luthe, L; Munjack, D; Pecknold, J, 1994) |
| "Panic disorder is a chronic illness with only some degree of spontaneous recovery." | 2.67 | Discontinuation reactions to alprazolam in panic disorder. ( Pecknold, JC, 1993) |
| " If a side effect profile is known, it will be easier for a clinician to choose the right drug and the appropriate management by taking into account compliance, safety and efficacy in each patient under treatment." | 2.67 | Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. ( Benkert, O; Cassano, GB; Curtis, G; Deltito, J; Hippius, H; Klerman, G; Maier, W; Petracca, A; Shera, D; Toni, C, 1994) |
| "5 years, 78% of patients remained on medication and the mean dosage of alprazolam and clonazepam did not increase." | 2.67 | Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. ( Cohen, LS; Meltzer-Brody, S; Otto, MW; Pollack, MH; Rosenbaum, JF; Tesar, GE, 1993) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 2.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| " The majority (67%) of patients interviewed discontinued alprazolam for a period of at least 3 days after a gradual dosage reduction schedule over a 4-week period at the end of the long-term treatment study." | 2.67 | Discontinuation of alprazolam after long-term treatment of panic-related disorders. ( Ballenger, JC; Burrows, GD; DuPont, RL; Noyes, R; Pecknold, JC; Rifkin, A; Rubin, RT; Swinson, RP, 1992) |
| "Help-seeking behaviour for treatment of panic disorder was investigated in the sample of the Cross-National Collaborative Panic Study Second Phase." | 2.67 | Center differences and cross-national invariance in help-seeking for panic disorder. A report from the cross-national collaborative panic study. ( Amering, M; Buller, R; Deltito, JA; Katschnig, H; Klerman, GL; Lavori, PW; Winter, P, 1992) |
| " Small sample sizes in many panic provocation studies, lack of dose-response aspects, and still-insufficient knowledge about the biological underpinning of experimental and spontaneous panic limit the interpretation of existing findings and should inspire further research." | 2.47 | Experimental panic provocation in healthy man-a translational role in anti-panic drug development? ( Kellner, M, 2011) |
| "Because the other standard treatments of panic disorder, the SSRIs, have a slow onset of action, adding an extended-release benzodiazepine to the treatment regimen for the initial 6 to 8 weeks could serve as an effective bridge until the desired SSRI effect is realized." | 2.41 | The management of panic disorder. ( Sheehan, DV, 2002) |
| "Clonazepam has several advantages over other benzodiazepines and can be considered a first-line agent for panic disorder." | 2.40 | Use of benzodiazepines in panic disorder. ( Davidson, JR, 1997) |
| "The etiology and optimum treatment of panic disorder remain unclear." | 2.39 | Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. ( Boyer, W, 1995) |
| "Drug treatment of panic disorder is reviewed with focus on recent controlled studies." | 2.38 | Drug treatment of panic disorder. ( Rosenberg, R, 1993) |
| "Panic disorder is a serious, often chronic condition that warrants vigorous treatment." | 2.38 | Psychopharmacological treatment of panic disorder. ( Bowden, CL, 1992) |
| " Chronic administration of both paroxetine and alprazolam decreased these responses with morphological correlates between the panicolytic effect of both drugs administered at the highest dose and decreases in Fos protein-immunolabeled perikarya found in the amygdaloid complex, hypothalamus and periaqueductal gray matter columns, which are structures that make up the encephalic aversion system." | 1.48 | The Rodent-versus-wild Snake Paradigm as a Model for Studying Anxiety- and Panic-like Behaviors: Face, Construct and Predictive Validities. ( Coimbra, JPC; Coimbra, NC; de Freitas, RL; Dos Anjos-Garcia, T; Falconi-Sobrinho, LL; Laure, CJ; Paschoalin-Maurin, T, 2018) |
| "Panic disorder is a severe anxiety disorder with recurrent, debilitating panic attacks." | 1.36 | A key role for orexin in panic anxiety. ( Brundin, L; Dietrich, A; Fitz, SD; Goddard, AW; Johnson, PL; Minick, PE; Sanghani, S; Shekhar, A; Träskman-Bendz, L; Truitt, W, 2010) |
| "The management of the patient's withdrawal symptoms is described." | 1.31 | Pharmacokinetically induced benzodiazepine withdrawal. ( Ninan, PT, 2001) |
| "Posttraumatic stress disorder (PTSD) and panic disorder (PD) share several clinical features, and theory postulates that phasic arousal is similarly dysregulated in both." | 1.30 | Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder. ( Bloch, M; Bonne, O; Peri, T; Shalev, AY, 1998) |
| "T cells from patients with untreated panic disorder exhibited significantly higher cholecystokinin-4-induced calcium mobilization than those from healthy controls or patients with treated panic disorder." | 1.29 | CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder. ( Akiyoshi, J; Fujii, I; Isogawa, K; Kuga, K; Miyamoto, M; Moriyama, T; Sasaki, I; Yamada, K; Yamamoto, H, 1996) |
| "In 2 patients Graves' disease occurred in the setting of previously established euthyroid panic disorder." | 1.29 | Graves'disease after the onset of panic disorder. ( Kubo, C; Matsubayashi, S; Matsumoto, Y; Morita, T; Mukuta, T; Tamagawa, K; Tamaí, H, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.53) | 18.7374 |
| 1990's | 139 (73.16) | 18.2507 |
| 2000's | 32 (16.84) | 29.6817 |
| 2010's | 16 (8.42) | 24.3611 |
| 2020's | 2 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Guaiana, G | 1 |
| Meader, N | 1 |
| Barbui, C | 1 |
| Davies, SJ | 1 |
| Furukawa, TA | 1 |
| Imai, H | 1 |
| Dias, S | 1 |
| Caldwell, DM | 1 |
| Koesters, M | 1 |
| Tajika, A | 1 |
| Bighelli, I | 1 |
| Pompoli, A | 1 |
| Cipriani, A | 1 |
| Dawson, S | 1 |
| Robertson, L | 1 |
| Batista, LA | 2 |
| Lopes, JB | 1 |
| Brianis, RC | 1 |
| Haibara, AS | 2 |
| Moreira, FA | 2 |
| Paschoalin-Maurin, T | 1 |
| Dos Anjos-Garcia, T | 1 |
| Falconi-Sobrinho, LL | 1 |
| de Freitas, RL | 1 |
| Coimbra, JPC | 1 |
| Laure, CJ | 1 |
| Coimbra, NC | 1 |
| Baltás, P | 1 |
| Páll, A | 1 |
| Becs, G | 1 |
| Erdei, A | 1 |
| Sira, L | 1 |
| Czifra, A | 1 |
| Barna, S | 1 |
| Kovács, P | 1 |
| Páll, D | 1 |
| Pfliegler, G | 1 |
| Paragh, G | 1 |
| Szabó, Z | 1 |
| Schenberg, LC | 1 |
| Okumura, A | 1 |
| Morii, A | 1 |
| Kiriyama, M | 1 |
| Takamatsu, H | 1 |
| Shimizu, M | 1 |
| Yasui, S | 1 |
| Takagawa, K | 1 |
| Bailey, JE | 1 |
| Papadopoulos, A | 1 |
| Seddon, K | 1 |
| Nutt, DJ | 1 |
| Rupprecht, R | 2 |
| Rammes, G | 1 |
| Eser, D | 2 |
| Baghai, TC | 2 |
| Schüle, C | 1 |
| Nothdurfter, C | 1 |
| Troxler, T | 1 |
| Gentsch, C | 1 |
| Kalkman, HO | 1 |
| Chaperon, F | 1 |
| Uzunov, V | 1 |
| McAllister, KH | 1 |
| Bertaina-Anglade, V | 1 |
| La Rochelle, CD | 1 |
| Tuerck, D | 1 |
| Floesser, A | 1 |
| Kiese, B | 1 |
| Schumacher, M | 1 |
| Landgraf, R | 1 |
| Holsboer, F | 1 |
| Kucher, K | 1 |
| Hooper, S | 1 |
| Bruno, R | 1 |
| Sharpe, M | 1 |
| Tahmindjis, A | 1 |
| Johnson, PL | 2 |
| Truitt, W | 1 |
| Fitz, SD | 2 |
| Minick, PE | 1 |
| Dietrich, A | 1 |
| Sanghani, S | 1 |
| Träskman-Bendz, L | 1 |
| Goddard, AW | 1 |
| Brundin, L | 1 |
| Shekhar, A | 2 |
| Otto, MW | 6 |
| McHugh, RK | 1 |
| Simon, NM | 1 |
| Farach, FJ | 1 |
| Worthington, JJ | 1 |
| Pollack, MH | 10 |
| Tamai, Y | 1 |
| Matsumoto, H | 1 |
| Sabljić, V | 1 |
| Rakun, R | 1 |
| Ružić, K | 1 |
| Grahovac, T | 1 |
| Roberson-Nay, R | 1 |
| Latendresse, SJ | 1 |
| Kendler, KS | 1 |
| Moylan, S | 2 |
| Staples, J | 1 |
| Ward, SA | 1 |
| Rogerson, J | 1 |
| Stein, DJ | 1 |
| Berk, M | 2 |
| Marazziti, D | 1 |
| Carlini, M | 1 |
| Dell'Osso, L | 1 |
| Kellner, M | 1 |
| Giorlando, F | 1 |
| Nordfjærn, T | 1 |
| Starcevic, V | 5 |
| Lampe, L | 1 |
| Engleman, EA | 1 |
| Svensson, KA | 1 |
| Schkeryantz, JM | 1 |
| Ninan, PT | 2 |
| Kolar, D | 1 |
| Latas, M | 1 |
| Bogojevic, G | 1 |
| Kelin, K | 1 |
| Sheehan, DV | 4 |
| Roy-Byrne, P | 1 |
| Russo, J | 1 |
| Pollack, M | 1 |
| Stewart, R | 1 |
| Bystrisky, A | 1 |
| Bell, J | 1 |
| Rosenbaum, J | 1 |
| Corrigan, MH | 1 |
| Stolk, J | 2 |
| Rush, AJ | 1 |
| Ballenger, J | 2 |
| Litvintsev, SV | 1 |
| Reznik, AM | 1 |
| Kvashnina, NV | 1 |
| Arbuzov, AL | 1 |
| Krylov, KE | 1 |
| Boerner, RJ | 1 |
| Andersch, S | 1 |
| Hetta, J | 1 |
| Verster, JC | 1 |
| Volkerts, ER | 1 |
| Rickels, K | 6 |
| Abelson, JL | 3 |
| Curtis, GC | 4 |
| Uhde, TW | 1 |
| Schreier, H | 1 |
| Martinez, K | 1 |
| Fiseković, S | 1 |
| Loga-Zec, S | 1 |
| Choi, YH | 1 |
| Vincelli, F | 1 |
| Riva, G | 1 |
| Wiederhold, BK | 1 |
| Lee, JH | 1 |
| Park, KH | 1 |
| Prasko, J | 1 |
| Houbová, P | 1 |
| Novák, T | 1 |
| Záleský, R | 1 |
| Espa-Cervená, K | 1 |
| Pasková, B | 1 |
| Vyskocilová, J | 1 |
| Uhlenhuth, EH | 5 |
| Leon, AC | 7 |
| Matuzas, W | 4 |
| Cerra, D | 1 |
| Hogg, S | 1 |
| Michan, L | 1 |
| Jessa, M | 1 |
| Zwanzger, P | 1 |
| Völkel, N | 1 |
| Möller, HJ | 1 |
| Padberg, F | 1 |
| Qualls, C | 2 |
| Antal, EJ | 2 |
| Javaid, JI | 2 |
| Barnhill, J | 2 |
| Himmerich, H | 1 |
| Nickel, T | 1 |
| Dalal, MA | 1 |
| Müller, MB | 1 |
| Béchir, M | 1 |
| Schwegler, K | 1 |
| Chenevard, R | 1 |
| Binggeli, C | 1 |
| Caduff, C | 1 |
| Büchi, S | 1 |
| Buddeberg, C | 1 |
| Lüscher, TF | 1 |
| Noll, G | 1 |
| Benjamin, AB | 1 |
| Sheehan, KH | 1 |
| Raj, BA | 1 |
| Virit, O | 1 |
| Savas, HA | 1 |
| Shear, MK | 4 |
| Rosenbaum, JF | 9 |
| Keller, MB | 3 |
| Marzuk, PM | 1 |
| Portera, L | 5 |
| Boyer, W | 1 |
| Bruce, TJ | 3 |
| Spiegel, DA | 5 |
| Gregg, SF | 2 |
| Nuzzarello, A | 2 |
| Brambilla, F | 6 |
| Bellodi, L | 6 |
| Perna, G | 6 |
| Bertani, A | 1 |
| Panerai, A | 3 |
| Sacerdote, P | 3 |
| Cowley, DS | 2 |
| Roy-Byrne, PP | 2 |
| Radant, A | 1 |
| Ritchie, JC | 1 |
| Greenblatt, DJ | 5 |
| Nemeroff, CB | 1 |
| Hommer, DW | 1 |
| O'Sullivan, GH | 1 |
| Noshirvani, H | 6 |
| Başoğlu, M | 10 |
| Marks, IM | 7 |
| Swinson, R | 2 |
| Kuch, K | 3 |
| Kirby, M | 1 |
| Pecknold, J | 2 |
| Luthe, L | 1 |
| Munjack, D | 1 |
| Alexander, P | 1 |
| Garberi, A | 2 |
| Nobile, P | 2 |
| Arancio, C | 1 |
| Shader, RI | 4 |
| Curran, HV | 3 |
| Bond, A | 1 |
| O'Sullivan, G | 5 |
| Bruce, M | 1 |
| Marks, I | 3 |
| Lelliot, P | 1 |
| Shine, P | 2 |
| Lader, M | 1 |
| Klein, DF | 1 |
| Swinson, RP | 6 |
| Kiliç, C | 4 |
| Brewin, CR | 1 |
| Rosenberg, NK | 1 |
| Rosenberg, R | 2 |
| Labbate, LA | 1 |
| Tesar, GM | 1 |
| Jonas, JM | 2 |
| Piper, A | 1 |
| Klein, E | 3 |
| Colin, V | 2 |
| Lenox, RH | 3 |
| Rosenfeld, DS | 1 |
| Furman, Y | 1 |
| Baron, C | 1 |
| Marcotte, JE | 1 |
| Sachs, GS | 3 |
| Leon, A | 3 |
| Deltito, JA | 3 |
| Sanderson, WC | 1 |
| Wetzler, S | 1 |
| Asnis, GM | 1 |
| Mant, A | 2 |
| Kaspi, SP | 1 |
| Hammerness, PG | 1 |
| Briggs, AC | 1 |
| Stretch, DD | 1 |
| Brandon, S | 2 |
| Tiffon, L | 1 |
| Coplan, JD | 1 |
| Papp, LA | 1 |
| Gorman, JM | 1 |
| Roberts, JM | 1 |
| Malcolm, R | 1 |
| Santos, AB | 1 |
| Roth, M | 2 |
| Weissman, M | 1 |
| Lavori, P | 2 |
| Gorman, J | 1 |
| Rush, J | 1 |
| Miyaoka, H | 1 |
| Nozaki, S | 1 |
| Kinami, Y | 1 |
| Kamishima, K | 1 |
| Massana, J | 1 |
| Udina, C | 1 |
| Ayuso, JL | 1 |
| Cassano, GB | 3 |
| Perugi, G | 1 |
| Pecknold, JC | 2 |
| Gelder, MG | 1 |
| Clark, DM | 1 |
| Salkovskis, P | 1 |
| Woodman, CL | 1 |
| Noyes, R | 3 |
| Ballenger, JC | 7 |
| Lydiard, RB | 3 |
| Sievers, G | 1 |
| Mihalko, D | 1 |
| Toni, C | 2 |
| Petracca, A | 1 |
| Deltito, J | 1 |
| Benkert, O | 2 |
| Curtis, G | 1 |
| Hippius, H | 1 |
| Maier, W | 2 |
| Shera, D | 2 |
| Klerman, G | 1 |
| Klerman, GL | 5 |
| Goldenberg, I | 1 |
| Olanoff, LS | 1 |
| Sellers, EM | 2 |
| von Moltke, LL | 1 |
| Harmatz, JS | 3 |
| Ciraulo, DA | 1 |
| Cohon, MS | 1 |
| Kravitz, HM | 1 |
| Fawcett, J | 1 |
| Newman, AJ | 1 |
| Lavori, PW | 3 |
| Goldenberg, IM | 1 |
| Baker, LA | 1 |
| Shear, K | 1 |
| Schweizer, E | 4 |
| Patterson, W | 1 |
| Rosenthal, M | 1 |
| Lepola, UM | 1 |
| Rimón, RH | 1 |
| Riekkinen, PJ | 1 |
| Raj, AB | 2 |
| Harnett-Sheehan, K | 2 |
| Soto, S | 1 |
| Knapp, E | 2 |
| Tesar, GE | 1 |
| Cohen, LS | 1 |
| Meltzer-Brody, S | 2 |
| Reiter, SR | 1 |
| Greist, J | 1 |
| Weiss, S | 2 |
| Zavodnick, S | 2 |
| Jolkkonen, J | 2 |
| Lepola, U | 3 |
| Bissette, G | 1 |
| Nemeroff, C | 1 |
| Riekkinen, P | 2 |
| Munjack, DJ | 1 |
| Brown, RA | 1 |
| Cabe, DD | 1 |
| McDowell, DE | 1 |
| Baltazar, PL | 1 |
| Shelton, RC | 1 |
| Harvey, DS | 1 |
| Stewart, PM | 1 |
| Loosen, PT | 1 |
| Dawson, R | 1 |
| Diukova, GM | 1 |
| Vorob'eva, OV | 1 |
| Petrova, EP | 1 |
| Smirnov, SV | 1 |
| Tumalaeva, ZN | 1 |
| Rimón, R | 1 |
| Halonen, T | 1 |
| Akiyoshi, J | 1 |
| Moriyama, T | 1 |
| Isogawa, K | 1 |
| Miyamoto, M | 1 |
| Sasaki, I | 1 |
| Kuga, K | 1 |
| Yamamoto, H | 1 |
| Yamada, K | 1 |
| Fujii, I | 1 |
| Fava, GA | 1 |
| Shioiri, T | 2 |
| Fujii, K | 1 |
| Someya, T | 1 |
| Takahashi, S | 2 |
| Koponen, H | 1 |
| Leinonen, E | 1 |
| Bond, AJ | 1 |
| Bruce, MS | 1 |
| Burrows, GD | 3 |
| Reich, JH | 1 |
| Judd, FK | 2 |
| Garvey, MJ | 1 |
| Norman, TR | 2 |
| Cook, BL | 1 |
| Marriott, P | 1 |
| Kita, N | 1 |
| Katschnig, H | 3 |
| Amering, M | 3 |
| Stolk, JM | 2 |
| Briggs, A | 1 |
| Buller, R | 4 |
| Cassano, G | 1 |
| Garvey, M | 1 |
| Hetem, LA | 1 |
| Zinder, O | 1 |
| Zilberman, I | 2 |
| Levy, N | 1 |
| Greenberg, A | 1 |
| Matsubayashi, S | 1 |
| Tamaí, H | 1 |
| Matsumoto, Y | 1 |
| Tamagawa, K | 1 |
| Mukuta, T | 1 |
| Morita, T | 1 |
| Kubo, C | 1 |
| Pols, H | 1 |
| Verburg, K | 1 |
| Hauzer, R | 1 |
| Meijer, J | 1 |
| Griez, E | 1 |
| Pollock, RA | 1 |
| Gold, PW | 1 |
| Davidson, JR | 1 |
| Barlow, DH | 1 |
| Olfson, M | 1 |
| Warner, TD | 1 |
| Thompson, PM | 1 |
| Dorotheo, J | 1 |
| Sheehan, MF | 1 |
| Trehan, R | 1 |
| Swiontek, A | 1 |
| Coleman, B | 1 |
| Roache, JD | 2 |
| Stanley, MA | 1 |
| Creson, DR | 1 |
| Shah, NN | 1 |
| Meisch, RA | 1 |
| Livanou, M | 1 |
| Wilhelm, FH | 1 |
| Roth, WT | 2 |
| Malel, D | 1 |
| Biron, CR | 1 |
| Shalev, AY | 1 |
| Bloch, M | 1 |
| Peri, T | 1 |
| Bonne, O | 1 |
| Matthews, J | 1 |
| Scott, EL | 1 |
| Fukuda, M | 1 |
| Takazawa, S | 1 |
| Nakagome, K | 1 |
| Iwanami, A | 1 |
| Hata, A | 1 |
| Kasai, K | 1 |
| Hiramatsu, K | 1 |
| Hegel, MT | 1 |
| Sheikh, JI | 1 |
| Swales, PJ | 1 |
| Lowell, K | 1 |
| Rheinheimer, D | 1 |
| Oswald, LM | 1 |
| Rhoades, HM | 1 |
| Kaplan, GB | 1 |
| Ehrenberg, BL | 1 |
| Goddard, JE | 1 |
| Gladsjo, JA | 1 |
| Rapaport, MH | 1 |
| McKinney, R | 1 |
| Auerbach, M | 1 |
| Hahn, T | 1 |
| Rabin, A | 1 |
| Oliver, T | 1 |
| Haze, A | 1 |
| Judd, LL | 1 |
| Sandyk, R | 1 |
| Dann, LC | 1 |
| Trochim, WM | 1 |
| Cappelleri, JC | 1 |
| Battaglia, M | 1 |
| Sciuto, G | 1 |
| Diaferia, G | 1 |
| Petraglia, F | 1 |
| León, CA | 1 |
| Arévalo, W | 1 |
| Gaviria, LF | 1 |
| Sengün, S | 1 |
| McCann, UD | 1 |
| Ricaurte, GA | 1 |
| Van Gool, D | 1 |
| Igodt, P | 1 |
| De Cuyper, H | 1 |
| Hommer, D | 1 |
| Kramer, GL | 1 |
| Petty, F | 1 |
| Watts-Jones, D | 1 |
| Lesser, IM | 2 |
| Antal, E | 1 |
| Rubin, RT | 3 |
| DuPont, R | 2 |
| Scheibe, G | 1 |
| Nutzinger, D | 1 |
| Walther, AU | 1 |
| Romach, MK | 1 |
| Somer, GR | 1 |
| Sobell, LC | 1 |
| Sobell, MB | 1 |
| Kaplan, HL | 1 |
| DuPont, RL | 1 |
| Rifkin, A | 1 |
| Cox, BJ | 1 |
| Endler, NS | 1 |
| Lee, PS | 1 |
| Albus, M | 1 |
| Zahn, TP | 1 |
| Breier, A | 1 |
| Musetti, L | 1 |
| van Balkom, AJ | 1 |
| van Dyck, R | 1 |
| Oosterbaan, D | 1 |
| Margraf, J | 1 |
| Ehlers, A | 1 |
| Haddad, JM | 1 |
| Maddock, RJ | 1 |
| Agras, WS | 1 |
| Taylor, CB | 1 |
| Woods, SW | 1 |
| Nagy, LM | 1 |
| Koleszar, AS | 1 |
| Krystal, JH | 1 |
| Heninger, GR | 1 |
| Charney, DS | 1 |
| Laraia, M | 1 |
| Korn, ML | 1 |
| Kotler, M | 1 |
| Molcho, A | 1 |
| Botsis, AJ | 1 |
| Grosz, D | 1 |
| Chen, C | 1 |
| Plutchik, R | 1 |
| Brown, SL | 1 |
| van Praag, HM | 1 |
| Glod, CA | 1 |
| Martin, T | 1 |
| Winter, P | 1 |
| Bowden, CL | 1 |
| Ravaris, CL | 1 |
| Friedman, MJ | 1 |
| Hauri, PJ | 1 |
| McHugo, GJ | 1 |
| Roth, SM | 1 |
| Argyle, N | 2 |
| Ross, CA | 1 |
| Clark, DB | 1 |
| Solyom, C | 1 |
| Solyom, L | 1 |
| Saran, A | 1 |
| Halaris, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Searching for Exosomal microRNAs and Cellular Biomarkers and Mechanisms Underlying the Differences Between Panic Disorder Patients Who Are Responders and Non-responders to Cognitive Behavior Therapy[NCT04029740] | 80 participants (Anticipated) | Interventional | 2019-03-24 | Recruiting | |||
| [NCT00004373] | Phase 2 | 80 participants | Interventional | 1997-03-31 | Completed | ||
| Age-based Cut-off Point as Methodological Approach in Search for Differences in Mortality and Revision for Fixation Type: Cemented Versus Uncemented Total Hip Arthroplasty[NCT05108155] | 43,789 participants (Actual) | Observational [Patient Registry] | 2007-01-31 | Completed | |||
| Patient-centered Treatment of Anxiety After Low-Risk Chest Pain in the Emergency Room[NCT04811521] | 375 participants (Anticipated) | Interventional | 2021-04-01 | Enrolling by invitation | |||
| Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding[NCT01451697] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for alprazolam and Panic Disorder
| Article | Year |
|---|---|
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipr | 2023 |
The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Humans; Panic Disorder; Psychiatric S | 2011 |
Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clomipramine; Cognit | 2012 |
Experimental panic provocation in healthy man-a translational role in anti-panic drug development?
Topics: Alprazolam; Anti-Anxiety Agents; Clinical Trials as Topic; Drug Design; Humans; Panic Disorder; Tetr | 2011 |
The role of alprazolam for the treatment of panic disorder in Australia.
Topics: Alprazolam; Anti-Anxiety Agents; Australia; Controlled Clinical Trials as Topic; Guideline Adherence | 2012 |
The management of panic disorder.
Topics: Alprazolam; Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Delayed-Act | 2002 |
[Panic attacks and panic disorder. Checklist for the diagnosis].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: a review of the literature.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Anxiety Disorders; Automobile Driving; Behavior; Clinical | 2004 |
Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.
Topics: Alprazolam; Double-Blind Method; Humans; Imipramine; Panic Disorder; Prospective Studies; Psychiatri | 1995 |
Pure sleep panic: two case reports and a review of the literature.
Topics: Adult; Alcoholism; Alprazolam; Arousal; Combined Modality Therapy; Depressive Disorder; Female; Huma | 1994 |
Drug treatment of panic disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Humans; Imipramine; Panic Disorder | 1993 |
Cognitive treatment for panic disorder.
Topics: Alprazolam; Arousal; Clinical Trials as Topic; Cognitive Behavioral Therapy; Humans; Imipramine; Pan | 1993 |
Medication discontinuation in panic disorder.
Topics: Alprazolam; Benzodiazepines; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Admini | 1993 |
Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications.
Topics: Alprazolam; Anxiety Disorders; Biotransformation; Clinical Trials as Topic; Cytochrome P-450 Enzyme | 1993 |
A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature.
Topics: Alprazolam; Antidepressive Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as | 1993 |
Alprazolam and depression: a review of risks and benefits.
Topics: Adolescent; Adult; Aged; Alprazolam; Benzodiazepines; Clinical Trials as Topic; Depressive Disorder; | 1993 |
Clinical issues in the long-term treatment of panic disorder.
Topics: Age Factors; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Child; Cognitive B | 1996 |
Use of benzodiazepines in panic disorder.
Topics: Alprazolam; Benzodiazepines; Clonazepam; Humans; Lorazepam; Panic Disorder; Treatment Outcome | 1997 |
Cognitive-behavioral therapy for panic disorder: current status.
Topics: Alprazolam; Cognitive Behavioral Therapy; Combined Modality Therapy; Controlled Clinical Trials as T | 1997 |
Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine.
Topics: Alprazolam; Behavior Therapy; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modal | 1997 |
Efficacy studies of alprazolam in panic disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Clinical Trials as Topic; Humans; Panic Disorder | 1998 |
Panic disorder: long-term pharmacotherapy and discontinuation.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Chronic Disease; Controlled Clini | 1998 |
Mode of action of the triazolobenzodiazepines in the treatment of panic attacks: a hypothesis.
Topics: Alprazolam; Anti-Anxiety Agents; Humans; Panic Disorder | 1992 |
Pharmacological and behavioural treatment of panic disorder.
Topics: Agoraphobia; Alprazolam; Humans; Panic Disorder | 1992 |
[Benzodiazepines as pharmacotherapeutic possibility in the treatment of panic disorders].
Topics: Alprazolam; Antidepressive Agents; Benzodiazepines; Clinical Trials as Topic; Double-Blind Method; H | 1992 |
Xanax: pros and cons.
Topics: Adult; Alprazolam; Anxiety Disorders; Depressive Disorder; Female; Humans; Panic Disorder; Stress Di | 1992 |
Psychopharmacological treatment of panic disorder.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Benzodiazepines; Depressive Disorder; Female; H | 1992 |
88 trials available for alprazolam and Panic Disorder
| Article | Year |
|---|---|
A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.
Topics: Administration, Inhalation; Adolescent; Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; C | 2009 |
Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects.
Topics: Adult; Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepines; Cell Line; Drug Tolerance; gamma-A | 2009 |
Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.
Topics: Adult; Alprazolam; Benzodiazepines; Clonazepam; Cognitive Behavioral Therapy; Dose-Response Relation | 2010 |
Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Pani | 2003 |
A 15-year follow-up study of patients with panic disorder.
Topics: Activities of Daily Living; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Sec | 2003 |
Alprazolam extended-release in panic disorder.
Topics: Alprazolam; Clinical Trials as Topic; Cross-Over Studies; Delayed-Action Preparations; Double-Blind | 2004 |
Twenty-four hour growth hormone secretion in patients with panic disorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Circadian Rhythm; Female; Human Growth Hormone; Humans; Hypo | 2005 |
Sertraline and alprazolam in the treatment of panic desorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 2005 |
Effects of group experiential cognitive therapy for the treatment of panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anticonvulsants; Clonazepam; Cognitive Behavior | 2005 |
Influence of personality disorder on the treatment of panic disorder--comparison study.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Cognitive Behavioral Therapy; Combined Modality | 2005 |
Psychopathology of panic attacks in panic disorder.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Cognition; Humans; I | 2006 |
Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
Topics: Adolescent; Adult; Affect; Alprazolam; Anti-Anxiety Agents; Blood Pressure; Cognition; Cognitive Beh | 2006 |
Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Age | 2007 |
The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Biological Availability; Cross-Over Studies; De | 2007 |
Pattern of placebo response in panic disorder.
Topics: Alprazolam; Follow-Up Studies; Humans; Imipramine; Panic Disorder; Placebo Effect; Time Factors; Tre | 1995 |
Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Combined Modality Therapy; Desensitization, Psychologic; Dose-Respon | 1994 |
A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder.
Topics: Adult; Alprazolam; Arousal; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Bl | 1994 |
Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Female; Growth Hormone; Growth Hormone-Releasing Hormone; | 1995 |
Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clonidine; Female; Humans; Hydrocortisone; Male; Middle Aged; Panic | 1995 |
Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder.
Topics: Adult; Affect; Agoraphobia; Alprazolam; Arousal; Combined Modality Therapy; Desensitization, Psychol | 1994 |
Panic disorder with agoraphobia.
Topics: Agoraphobia; Alprazolam; Combined Modality Therapy; Desensitization, Psychologic; Humans; Panic Diso | 1993 |
Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure.
Topics: Adult; Agoraphobia; Alprazolam; Combined Modality Therapy; Depressive Disorder; Desensitization, Psy | 1994 |
Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Arousal; Combined Modality Therapy; Desensitizati | 1994 |
Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse.
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Combined Modality Therapy; Desensitization, Psychologic; Fe | 1994 |
Three years follow-up of panic disorder patients: a naturalistic study.
Topics: Adult; Alprazolam; Analysis of Variance; Chronic Disease; Female; Follow-Up Studies; Humans; Imipram | 1994 |
The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma.
Topics: Adolescent; Adult; Alprazolam; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Dr | 1994 |
Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.
Topics: Adult; Alprazolam; Anxiety Disorders; Carbamazepine; Double-Blind Method; Drug Administration Schedu | 1994 |
Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo.
Topics: Adult; Aged; Alprazolam; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Humans; Imip | 1994 |
Alprazolam blockade of CO2-provoked panic in patients with panic disorder.
Topics: Administration, Inhalation; Adult; Alprazolam; Carbon Dioxide; Dose-Response Relationship, Drug; Dou | 1994 |
Cognitive behavior therapy for treatment-refractory panic disorder.
Topics: Adult; Alprazolam; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluo | 1994 |
Subtyping of panic disorder by symptom profile.
Topics: Adult; Alprazolam; Colombia; Europe; Female; Humans; Imipramine; Interview, Psychological; Linear Mo | 1993 |
Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Combined Modality Therapy; Desensitization, Psycho | 1993 |
Maintenance drug therapy of panic disorder.
Topics: Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imipramine; | 1993 |
Discontinuation reactions to alprazolam in panic disorder.
Topics: Agoraphobia; Alprazolam; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Adminis | 1993 |
Predictors of response to alprazolam and placebo in patients with panic disorder.
Topics: Adult; Alprazolam; Arousal; Double-Blind Method; Female; Humans; Male; Middle Aged; Panic Disorder; | 1994 |
Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?
Topics: Adult; Alprazolam; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Ad | 1994 |
Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo.
Topics: Adolescent; Adult; Aged; Alprazolam; Double-Blind Method; Humans; Imipramine; Middle Aged; Panic Dis | 1994 |
A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression.
Topics: Adult; Aged; Alprazolam; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; | 1993 |
Upjohn answers Consumer Reports.
Topics: Adverse Drug Reaction Reporting Systems; Alprazolam; Anxiety Disorders; Drug Industry; Humans; Panic | 1993 |
Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo.
Topics: Adult; Aged; Alprazolam; Arousal; Depressive Disorder; Double-Blind Method; Female; Humans; Imiprami | 1993 |
Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
Topics: Administration, Oral; Adolescent; Adult; Alprazolam; Delayed-Action Preparations; Double-Blind Metho | 1993 |
Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; D | 1993 |
Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; D | 1993 |
Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder.
Topics: Adult; Alprazolam; Clonazepam; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Panic D | 1993 |
Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder.
Topics: Adult; Alprazolam; Ambulatory Care; Benzodiazepines; Clonazepam; Cognitive Behavioral Therapy; Combi | 1993 |
Drug treatment of panic disorder. Further comment.
Topics: Alprazolam; Bias; Combined Modality Therapy; Follow-Up Studies; Humans; Panic Disorder; Psychotherap | 1993 |
Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Me | 1993 |
Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper.
Topics: Adult; Alprazolam; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 1993 |
A multiple imputation strategy for clinical trials with truncation of patient data.
Topics: Adult; Alprazolam; Ambulatory Care; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Bayes The | 1995 |
[The efficacy of alprazolam in the therapy of panic disorders].
Topics: Adolescent; Adult; Alprazolam; Anti-Anxiety Agents; Female; Humans; Male; Middle Aged; Panic Disorde | 1995 |
Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Female; GABA Modulators; gamma-Aminobutyric Aci | 1995 |
Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic | 1996 |
Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
Topics: Adult; Aggression; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Arousal; Competitive Behavior; Doub | 1995 |
Diazepam versus alprazolam for the treatment of panic disorder.
Topics: Adult; Age of Onset; Alprazolam; Diazepam; Double-Blind Method; Drug Administration Schedule; Female | 1996 |
Long-term follow-up after a drug trial for panic disorder.
Topics: Adolescent; Adult; Aged; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Dose-Res | 1995 |
Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Arousal; Carbon Dioxide; Cross-Over Studies; Do | 1996 |
Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial.
Topics: Alprazolam; Follow-Up Studies; Humans; Imipramine; Panic Disorder; Prognosis; Prospective Studies; Q | 1996 |
Service utilization and expenditures for the treatment of panic disorder.
Topics: Adult; Alprazolam; Ambulatory Care; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Community | 1997 |
Growing placebo response rate: the problem in recent therapeutic trials?
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Double- | 1997 |
Alprazolam-reinforced medication use in outpatients with anxiety.
Topics: Adult; Alprazolam; Analysis of Variance; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Addictive | 1997 |
Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial.
Topics: Agoraphobia; Alprazolam; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedul | 1997 |
Acute and delayed effects of alprazolam on flight phobics during exposure.
Topics: Adult; Aircraft; Alprazolam; Analysis of Variance; Anti-Anxiety Agents; Anxiety; Case-Control Studie | 1997 |
Subjective experience and attitudes towards participation in clinical trials among patients with anxiety disorders.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Female; Humans; Male; Panic Disorder; Pat | 1997 |
Panic disorder: long-term pharmacotherapy and discontinuation.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Chronic Disease; Controlled Clini | 1998 |
Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies.
Topics: Alprazolam; Benzodiazepines; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow | 1999 |
Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Follow-Up Studies; Humans; Male; Memory | 1999 |
Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
Topics: Aged; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Dose-Response Relationship, | 1999 |
A strategy to evaluate a covariate by group interaction in an analysis of covariance.
Topics: Alprazolam; Analysis of Variance; Anti-Anxiety Agents; Data Interpretation, Statistical; Humans; Mod | 1998 |
Predictors of individual differences in alprazolam self-medication.
Topics: Adult; Affect; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Huma | 1999 |
Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Cross-Over Studies; Double-Blind Method; Electroencephalogra | 2000 |
Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder.
Topics: Adult; Alprazolam; Analysis of Variance; Anti-Anxiety Agents; Attention; Delayed-Action Preparations | 2001 |
Drug treatment of panic disorder. Reply to comment by Marks and associates.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Cross-Cultural Comparison; Dose-Response Relationship, D | 1992 |
[Patients with panic disorder: a 5-year follow-up study].
Topics: Adult; Alprazolam; Double-Blind Method; Female; Follow-Up Studies; Humans; Imipramine; Male; Middle | 1992 |
Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Diazepam; gamma-Aminobutyric Acid; Humans | 1992 |
Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
Topics: Adult; Agoraphobia; Alprazolam; Clinical Protocols; Dose-Response Relationship, Drug; Double-Blind M | 1992 |
Pretreatment anxiety level as differential predictor in outpatients with panic disorder.
Topics: Adult; Alprazolam; Anxiety; Female; Humans; Imipramine; Male; Outpatients; Panic Disorder; Prognosis | 1992 |
Discontinuation of alprazolam after long-term treatment of panic-related disorders.
Topics: Adult; Alprazolam; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Female; Follow | 1992 |
Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures.
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Female; Galvanic Skin Response; Heart Rate; Humans; Hydroco | 1992 |
Treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Panic Disorde | 1992 |
Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators.
Topics: Adult; Alprazolam; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Imipramine; Neurops | 1992 |
Imipramine and alprazolam effects on stress test reactivity in panic disorder.
Topics: Adult; Alprazolam; Anxiety; Arrhythmias, Cardiac; Blood Pressure; Carbon Dioxide; Cold Temperature; | 1992 |
Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder.
Topics: Adolescent; Adult; Aged; Alprazolam; Analysis of Variance; Double-Blind Method; Drug Therapy, Combin | 1992 |
A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Arousal; Dose-Response Relationship, Drug; Double- | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Center differences and cross-national invariance in help-seeking for panic disorder. A report from the cross-national collaborative panic study.
Topics: Adult; Alprazolam; Cross-Cultural Comparison; Cross-Sectional Studies; Female; Humans; Imipramine; I | 1992 |
A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1991 |
Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Double-Blind Method; Fear; Female; Humans; Imipramine; Male | 1991 |
The structure of phobias in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; | 1991 |
76 other studies available for alprazolam and Panic Disorder
| Article | Year |
|---|---|
Intravenous doxapram administration as a potential model of panic attacks in rats.
Topics: Administration, Intravenous; Alprazolam; Animals; Benzamides; Carbamates; Central Nervous System Sti | 2021 |
The Rodent-versus-wild Snake Paradigm as a Model for Studying Anxiety- and Panic-like Behaviors: Face, Construct and Predictive Validities.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Anxiety; Dose-Response Relationship, Drug; Elapidae; Escap | 2018 |
[Family malediction in the background of panic disorder -- case report].
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Citalopra | 2013 |
Pseudopheochromocytoma induced by anxiolytic withdrawal.
Topics: Adrenal Gland Neoplasms; Alprazolam; Anti-Anxiety Agents; Female; Headache; Humans; Hypertension; Mi | 2014 |
Effects of alprazolam and cannabinoid-related compounds in an animal model of panic attack.
Topics: Alprazolam; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoxazines; Blood Pressure; Cannab | 2017 |
A CASE OF ADVANCED NON-SEMINOMATOUS TESTICULAR GERM CELL TUMOR ACCOMPANIED PANIC DISORDER.
Topics: Adult; alpha-Fetoproteins; Alprazolam; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2016 |
Alprazolam prescribing in Tasmania: a two-fold intervention designed to reduce inappropriate prescribing and concomitant opiate prescription.
Topics: Alprazolam; Analgesics, Opioid; Australia; Drug Prescriptions; Drug Utilization; Guidelines as Topic | 2009 |
A key role for orexin in panic anxiety.
Topics: Adult; Alprazolam; Animals; Anxiety; Disease Models, Animal; Female; Humans; Hypothalamus; Intracell | 2010 |
11-year-old boy with panic disorder responding to paroxetine.
Topics: Alprazolam; Anti-Anxiety Agents; Child; Humans; Male; Neuropsychological Tests; Panic Disorder; Paro | 2007 |
Duloxetine-related panic attacks.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Dose-Respo | 2011 |
A latent class approach to the external validation of respiratory and non-respiratory panic subtypes.
Topics: Age of Onset; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Diagnostic and Statistical Man | 2012 |
Reconsidering benzodiazepines in the treatment of panic disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Humans; Panic Disorder | 2012 |
Commentary on 'The role of alprazolam for the treatment of panic disorder in Australia'.
Topics: Alprazolam; Anti-Anxiety Agents; Humans; Panic Disorder | 2012 |
Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Cardiovascular System; gamma-Am | 2013 |
Pharmacokinetically induced benzodiazepine withdrawal.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Inter | 2001 |
Panic disorder patients at the time of air strikes.
Topics: Adult; Agoraphobia; Aircraft; Alprazolam; Catchment Area, Health; Clonazepam; Female; Follow-Up Stud | 2002 |
Xanax XR for panic disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Delayed-Action Preparations; Drug Interactions; Humans; Panic Disor | 2003 |
[Clinical picture and treatment of agoraphobia with panic disorder].
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Humans; Middle Aged; Military | 2003 |
Panic symptoms without report of anxiety.
Topics: Adolescent; Alprazolam; Anti-Anxiety Agents; Anxiety; Child; Diagnostic and Statistical Manual of Me | 2005 |
Trimipramine for refractory panic attacks.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Drug Resistance; Drug Therapy, Combination; Hum | 2006 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, | 2006 |
Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
Topics: Adrenocorticotropic Hormone; Adult; Alprazolam; Anti-Anxiety Agents; Area Under Curve; Female; Heart | 2007 |
[Gabapentin treatment in a female patient with panic disorder and adverse effects under carbamazepine during benzodiazepine withdrawal].
Topics: Aged; Alprazolam; Amines; Antimanic Agents; Benzodiazepines; Carbamazepine; Chemical and Drug Induce | 2007 |
Medication management with panic disorder in the exercise state: some prescribing guidelines.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Dose-Response Relationship, Drug; Drug Prescriptions; Exerci | 2007 |
Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
Topics: Adolescent; Adult; Alprazolam; Anti-Anxiety Agents; Anxiety; Cognition; Depression; Diagnostic and S | 2008 |
Citalopram-associated spontaneous ejaculations.
Topics: Adult; Alprazolam; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; | 2008 |
More reliable outcome measures can reduce sample size requirements.
Topics: Alprazolam; Depressive Disorder; Humans; Imipramine; Panic Disorder; Placebos; Psychiatric Status Ra | 1995 |
Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder.
Topics: Adult; Alprazolam; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Administration Sche | 1995 |
Plasma interleukin-1 beta concentrations in panic disorder.
Topics: Adult; Alprazolam; Amitriptyline; Antibodies, Monoclonal; Anxiety; Benzodiazepines; Cytokines; Femal | 1994 |
Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment.
Topics: Adult; Alprazolam; Diazepam; Dose-Response Relationship, Drug; Drug Tolerance; Female; Growth Hormon | 1995 |
Is there anything new on the use of psychotropic drugs during pregnancy?
Topics: Abnormalities, Drug-Induced; Adult; Alprazolam; Anti-Anxiety Agents; Female; Humans; Infant, Newborn | 1994 |
Upjohn responds to Consumer Reports letter.
Topics: Alprazolam; Anxiety Disorders; Clinical Trials as Topic; Drug Industry; Drug Utilization; Humans; Pa | 1994 |
Response to "high anxiety".
Topics: Alprazolam; Anxiety Disorders; Dose-Response Relationship, Drug; Female; Humans; Panic Disorder; Ris | 1994 |
Role of panic attacks in the intractability of asthma in children.
Topics: Alprazolam; Asthma; Child, Preschool; Humans; Male; Panic Disorder | 1994 |
Alprazolam utilisation in 1991.
Topics: Alprazolam; Humans; Panic Disorder | 1994 |
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Desipramine; Drug Therapy, Combination; Female; | 1994 |
Treatment of panic disorder and comorbid substance abuse with divalproex sodium.
Topics: Adult; Alprazolam; Comorbidity; Humans; Male; Panic Disorder; Substance-Related Disorders; Treatment | 1994 |
[Drug therapy of panic disorder and prediction of its therapeutic responses].
Topics: Adult; Alprazolam; Female; Humans; Male; Panic Disorder; Prognosis | 1993 |
Panic disorders and the listing of alprazolam on authority on the PBS. Beware of overdiagnosis.
Topics: Alprazolam; Diagnostic Errors; Humans; Panic Disorder | 1994 |
Lymphocyte cholecystokinin concentrations in panic disorder.
Topics: Adolescent; Adult; Alprazolam; Child; Female; Humans; Lymphocytes; Male; Panic Disorder; Severity of | 1993 |
The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Alprazolam; Benzodiazepines; Buspirone; Comorbidity; Depressive Disorder; Double- | 1993 |
CSF corticotropin-releasing factor is not affected in panic disorder.
Topics: Adult; Alprazolam; Corticotropin-Releasing Hormone; Female; Humans; Male; Panic Disorder | 1993 |
A naturalistic follow-up of panic patients after short-term pharmacologic treatment.
Topics: Adult; Alprazolam; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Age | 1993 |
Alprazolam in panic disorder: a retrospective analysis.
Topics: Adult; Agoraphobia; Alprazolam; Depressive Disorder; Female; Humans; Male; Panic Disorder; Psychiatr | 1993 |
Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Alprazolam; Circadian Rhythm; Female; Follow-Up Stud | 1996 |
CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder.
Topics: Adult; Alprazolam; Biomarkers; Calcium; Dose-Response Relationship, Drug; Female; Humans; Male; Midd | 1996 |
Anxiety sensitivity.
Topics: Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Cognitive Behavioral Therapy; Combined | 1996 |
A naturalistic 6-year follow-up study of patients with panic disorder.
Topics: Adult; Alcoholism; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Comorbidity; D | 1996 |
Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Female; Humans; Hyperprolactinemia; Middle Aged; Panic Disor | 1996 |
Addition of d-fenfluramine to benzodiazepines produces a marked improvement in refractory panic disorder--a case report.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Clonazepam; Drug Resistance; Female; Fenfluramine; Humans; P | 1996 |
Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder.
Topics: Adrenocorticotropic Hormone; Adult; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Catecholamin | 1995 |
Graves'disease after the onset of panic disorder.
Topics: Alprazolam; Anxiety Disorders; Benzodiazepines; Female; Graves Disease; Humans; Hyperthyroidism; Lif | 1996 |
Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment.
Topics: Adrenocorticotropic Hormone; Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Arousal; Corticotr | 1997 |
Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Delayed-Ac | 1996 |
Personality dimensions in panic disorder before and after effective treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Humans; Male; Middle Aged; Panic Disord | 1996 |
Agoraphobia and panic disorder: 3.5 years after alprazolam and/or exposure treatment.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Follow-Up Studies; Humans; Male; Panic | 1997 |
Calm response soothes patients' panic attacks, but nervousness needs to be addressed earlier.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Dental Anxiety; Female; Humans; Panic Disorder | 1996 |
Alprazolam reduces response to loud tones in panic disorder but not in posttraumatic stress disorder.
Topics: Acoustic Stimulation; Adult; Alprazolam; Arousal; Auditory Perception; Blinking; Diagnosis, Differen | 1998 |
Gabapentin as a potential treatment for anxiety disorders.
Topics: Acetates; Adult; Alprazolam; Amines; Anticonvulsants; Anxiety Disorders; Cyclohexanecarboxylic Acids | 1998 |
Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Dose-Response Relationship, Drug; Hormones; Humans; Hydrocor | 1998 |
Experimental procedures and the placebo response.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Humans; Imipramine; Panic Disorde | 1998 |
Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy.
Topics: Adult; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Female; Humans; Male; Middle Aged; Panic Disord | 1999 |
Seasonal panic disorder: a possible variant of seasonal affective disorder.
Topics: Adult; Alprazolam; Anxiety Disorders; Circadian Rhythm; Combined Modality Therapy; Depressive Disord | 1992 |
Cutoff assignment strategies for enhancing randomized clinical trials.
Topics: Alprazolam; Bias; Ethics, Medical; Humans; Models, Statistical; Panic Disorder; Personality Inventor | 1992 |
Psychoimmunoendocrine aspects of panic disorder.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Agoraphobia; Alprazolam; beta-Endorphin; Corticotrop | 1992 |
A prospective study of panic and anxiety in agoraphobia with panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Arousal; Combined Modality Therapy; Desensitizati | 1992 |
MDMA ("ecstasy") and panic disorder: induction by a single dose.
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Adult; Alprazolam; Anxiety Disorders; Arousal; | 1992 |
Cultural and integrative therapy issues in the treatment of a Jamaican woman with panic disorder.
Topics: Adult; Alprazolam; Culture; Ethnicity; Female; Humans; Jamaica; Panic Disorder; Psychotherapy; Unite | 1992 |
Characteristics of long-term alprazolam users in the community.
Topics: Alprazolam; Attitude to Health; Depressive Disorder; Drug Administration Schedule; Humans; Panic Dis | 1992 |
A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
Topics: Agoraphobia; Alprazolam; Female; Humans; Imipramine; Male; Panic Disorder; Psychiatric Status Rating | 1992 |
Suicide and violence associated with panic attacks.
Topics: Adult; Alprazolam; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; | 1992 |
Xanax can lead to dependency.
Topics: Alprazolam; Humans; Panic Disorder; Substance-Related Disorders | 1992 |
Adverse reaction to generic alprazolam.
Topics: Alprazolam; Drugs, Generic; Female; Humans; Middle Aged; Panic Disorder; Recurrence | 1991 |
Follow-up study of patients with panic disorder.
Topics: Alprazolam; Antidepressive Agents, Tricyclic; Behavior Therapy; Combined Modality Therapy; Follow-Up | 1991 |
Surreptitious drug use by panic disorder patients.
Topics: Alprazolam; Clinical Trials as Topic; Humans; Imipramine; Panic Disorder; Placebos; Self Medication | 1991 |
Panic attack precipitated by fluoxetine.
Topics: Adult; Alprazolam; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Panic Disorder; Psychiat | 1989 |